Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Champions Oncology (CSBR) Current Deferred Revenue (2016 - 2026)

Champions Oncology has reported Current Deferred Revenue over the past 16 years, most recently at $10.0 million for Q1 2026.

  • For Q1 2026, Current Deferred Revenue fell 8.46% year-over-year to $10.0 million; the TTM value through Jan 2026 reached $10.0 million, down 8.46%, while the annual FY2025 figure was $15.4 million, 27.69% up from the prior year.
  • Current Deferred Revenue for Q1 2026 was $10.0 million at Champions Oncology, down from $12.3 million in the prior quarter.
  • Over five years, Current Deferred Revenue peaked at $15.4 million in Q2 2025 and troughed at $8.7 million in Q1 2022.
  • A 5-year average of $11.8 million and a median of $11.2 million in 2022 define the central range for Current Deferred Revenue.
  • Biggest five-year swings in Current Deferred Revenue: skyrocketed 98.87% in 2022 and later dropped 21.38% in 2024.
  • Year by year, Current Deferred Revenue stood at $11.2 million in 2022, then increased by 16.07% to $13.0 million in 2023, then decreased by 21.38% to $10.2 million in 2024, then rose by 20.72% to $12.3 million in 2025, then dropped by 18.97% to $10.0 million in 2026.
  • Business Quant data shows Current Deferred Revenue for CSBR at $10.0 million in Q1 2026, $12.3 million in Q4 2025, and $14.4 million in Q3 2025.